TrialScope Launches Global Compliance Tool
Introduces new solution to target multi-billion dollar global disclosure risks
Jersey City, NJ – TrialScope, the global leader in clinical trial transparency and compliance solutions, today announced the launch of ATLAS Global Compliance, a Software-as-a-Service (SaaS) solution that ensures clinical trial sponsors are tracking and managing global clinical trial disclosure compliance appropriately.
ATLAS enables sponsors to quickly ensure that their trials are compliant by combining key information from all sites in the trial into one, easily accessible view.
ATLAS addresses the issues within global disclosure and compliance that pose the greatest challenges to trial sponsors, including:
- Identifying and managing local or regional disclosure requirements
- Ensuring the sponsor’s disclosure policies are in effect
- Tracking disclosure performance against requirements and policies
ATLAS is designed to support sponsors of all sizes, providing critical compliance and disclosure oversight through an easy-to-implement SaaS solution. For sponsors who are managing multiple sites in multiple geographies, ATLAS ensures all compliance and disclosure requirements are met, eliminating potential costs and delays in the trial.
Mark Heinold, TrialScope CEO, noted, “ATLAS and the expansion of TrialScope’s portfolio of transparency and compliance solutions, reflect two shifts in the marketplace: increased complexity and risk and a growing need for broader, more meaningful views of global transparency initiatives. We are committed to supporting disclosure and transparency efforts that ultimately provide a better understanding of clinical research around the world.”
Clinical trial sponsors seeking more information about TrialScope’s ATLAS Global Compliance can register for a complimentary webinar on April 26, 2017.
About TrialScopeTrialScope simplifies the complexities of clinical trial transparency. TrialScope’s award-winning, proven solutions have been implemented successfully and rigorously tested in the most complex environments and are managing disclosures for roughly 35% of industry sponsored clinical trials. The company’s market-driven solutions and expertise enable sponsors to improve performance, mitigate compliance risk, and ultimately optimize efficiencies with clinical content lifecycle management tools, expertise and processes. TrialScope technologies are offered via a validation-ready SaaS platform hosted in a private cloud.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
